throbber

`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_______________
`
`RIMFROST AS
`
`Petitioner
`
`v.
`
`AKER BIOMARINE ANTARCTIC AS
`
`Patent Owner
`_______________
`
`Case No.: IPR2020-01533
`
`U.S. Patent No. 9,816,046
`
`Issue Date: November 14, 2017
`
`Title: Bioeffective Krill Oil Compositions
`
`_______________
`
`PETITION FOR INTER PARTES REVIEW
`
`UNDER 35 U.S.C. §§ 311-319 AND 37 C.F.R. § 42.1 ET SEQ.
`
`
`
`
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`
`U.S. Patent No. 9,816,046
`
`TABLE OF CONTENTS
`I.
`INTRODUCTION .......................................................................................... 1
`II. MANDATORY NOTICES ............................................................................ 3
`A.
`Real parties-in-interest ......................................................................... 3
`B.
`Related matters (37 C.F.R. § 42.8(b)(2)) ............................................. 3
`C.
`Counsel (37 C.F.R. §§ 42.8(b)(3) and 42.10(a)) .................................. 7
`D.
`Service information (37 C.F.R. § 42.8(b)(4)) ...................................... 8
`PATENT OFFICE FEES ................................................................................ 9
`III.
`IV. ADDITIONAL REQUIREMENTS FOR INTER PARTES REVIEW ........... 9
`A. Grounds for Standing (37 C.F.R. § 42.104(a)) .................................... 9
`B.
`Level or Ordinary Skill in the Art ........................................................ 9
`C.
`Identification of Challenge and Relief Requested
`(37 C.F.R. § 42.104(b) and 37 C.F.R. § 42.22(a)(1)) ........................ 10
`1.
`Claims for which Inter Partes Review is Requested
`(37 C.F.R. § 42.104(b)(2)) ....................................................... 10
`Specific Statutory Grounds on which the Challenge is
`Based (37 C.F.R. § 42.104(b)(2)) ............................................10
`Earliest Effective Priority Date ................................................11
`3.
`Prior Art References ................................................................11
`4.
`Claim Construction – Ordinary and Customary Meaning
`(37 C.F.R. § 42.104(b)(3)) .................................................................13
`35 U.S.C. § 325(d) Does Not Preclude This Petition ........................14
`
`2.
`
`D.
`
`E.
`
`
`
`- i -
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`V.
`
`U.S. Patent No. 9,816,046
`
`SUMMARY OF THE ‘046 PATENT ..........................................................15
`A.
`State of the Art ...................................................................................15
`B.
`Prior Art ..............................................................................................19
`1.
`Breivik II (Exhibit 1037) .........................................................19
`2.
`Yoshitomi (Exhibit 1033) ........................................................ 21
`3.
`Budziński (Exhibit 1008) ......................................................... 22
`4.
`Fricke (Exhibit 1010) ............................................................... 23
`5.
`Bottino II (Exhibit 1038) .........................................................24
`6.
`Randolph (Exhibit 1011) .......................................................... 26
`7.
`Sampalis I (Exhibit 1012) ........................................................27
`Background of the ‘046 Patent ...........................................................28
`Prosecution History of the ‘046 Patent ..............................................29
`Construction of the ‘046 Patent Claim Terms ....................................32
`1.
`Claims 1 and 13 – “krill oil” ....................................................33
`2.
`Claims 1 and 13 – “polar solvent” ...........................................33
`3.
`Claims 1 and 13 – “astaxanthin ester” .....................................34
`4.
`Claims 1 and 13 – “krill meal” ................................................ 35
`5.
`Claims 1 and 13 – “destroy the activity of lipases and
` phospholipases” .......................................37
`
`C.
`D.
`E.
`
`
`
`- ii -
`
`

`

`U.S. Patent No. 9,816,046
`
`Inter Partes Review Case No.: IPR2020-01533
`
`
`VI. COLLATERAL ESTOPPEL PRECLUDES PATENT OWNER
`FROM ADVANCING THE SAME PATENTABILITY
`ARGUMENTS REJECTED IN 877 FWD, 905 FWD, 765 FWD,
`453 FWD AND 752 FWD ............................................................................38
`VII. EACH GROUND PROVIDES MORE THAN A REASONABLE
`LIKELIHOOD THAT EACH CLAIM OF THE ‘046 PATENT IS
`UNPATENTABLE .......................................................................................40
`A. Ground 1: § 103(a) – Breivik II, Yoshitomi, Budziński, Fricke,
`Bottino II, Sampalis I [Claims 1-10] ..................................................41
`1.
`Claim 1 .....................................................................................41
`(a)
`The method steps of claim 1 ..........................................42
`(i)
`Obtaining krill meal by treating krill to destroy
`the activity of lipases and phospholipases ..........42
`Storing krill meal .................................................44
`(ii)
`(iii) Extracting krill oil with a polar solvent ...............45
`(b) Krill oil with greater than 30% phosphatidylcholine
`and astaxanthin esters ....................................................45
`Claim 2 .....................................................................................46
`Claim 3 .....................................................................................47
`Claim 4 .....................................................................................47
`Claim 5 .....................................................................................48
`Claim 6 .....................................................................................48
`Claim 7 .....................................................................................49
`Claim 8 .....................................................................................49
`
`2.
`3.
`4.
`5.
`6.
`7.
`8.
`
`
`
`- i -
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`
`U.S. Patent No. 9,816,046
`
`B.
`
`C.
`
`Claim 9 .....................................................................................50
`9.
`10. Claim 10 ...................................................................................50
`Ground 2: § 103(a) – Breivik II, Yoshitomi, Budziński, Fricke,
`Bottino II and Randolph [Claims 11-12] ...........................................57
`1.
`Claims 11-12 ............................................................................57
`Ground 3: § 103(a) – Breivik II, Budziński, Fricke, Yoshitomi,
`Bottino II, Randolph and Sampalis I [Claims 13-19] ........................60
`1.
`Claim 13 ...................................................................................60
`(a)
`The method steps of claim 12 ........................................ 61
`(i)
`Obtaining Euphausia superba krill meal by
`treating to destroy the activity of lipases and
`phospholipases .....................................................61
`Storing krill meal .................................................62
`(ii)
`(iii) Extracting krill oil with a polar solvent ...............62
`Claim 14 ...................................................................................64
`2.
`Claim 15 ...................................................................................64
`3.
`Claim 16 ...................................................................................65
`4.
`Claim 17 ...................................................................................65
`5.
`Claim 18 ...................................................................................65
`6.
`Claim 19 ...................................................................................66
`7.
`CLAIM CHART .................................................................................69
`D.
`VIII. CONCLUSION .............................................................................................89
`
`
`
`- ii -
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`IX. Certificate of Compliance .............................................................................90
`
`U.S. Patent No. 9,816,046
`
`
`
`- iii -
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`
`U.S. Patent No. 9,816,046
`
`APPENDIX OF EXHIBITS
`
`EXHIBIT NO. EXHIBIT DESCRIPTION
`1001
`
`U.S. Patent No. 9,816,046, issued November 14, 2017.
`
`1002
`
`U.S. Provisional Patent Application No. 61/024,072, filed
`January 28, 2008 (‘072 Provisional).
`
`U.S. Provisional Patent Application No. 60/983,446, filed
`October 29, 2007 (‘446 Provisional).
`
`U.S. Provisional Patent Application No. 60/975,058, filed
`September 25, 2007 (‘058 Provisional).
`
`U.S. Provisional Patent Application No. 60/920,483, filed
`March 28, 2007 (‘483 Provisional).
`
`Declaration of Stephen Tallon.
`
`Bottino, N.R., “The Fatty Acids of Antarctic Phytoplankton and
`Euphausiids. Fatty Acid Exchange among Trophic Levels of the
`Ross Sea,” 1974, Marine Biology, 27, 197-204 (Bottino I).
`
`Budziński, E., P. Bykowski and D. Dutkiewicz, 1985,
`Possibilities of processing and marketing of products made
`from Antarctic krill. FAO Fish.Tech. Pap., (268):46,
`(Budzinski).
`
`Catchpole and Tallon, WO 2007/123424, published November
`1, 2007, “Process for Separating Lipid Materials,” (Catchpole).
`
`- iv -
`
`
`1003
`
`
`1004
`
`
`1005
`
`
`1006
`
`1007
`
`
`1008
`
`
`1009
`
`
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`1010
`
`U.S. Patent No. 9,816,046
`
`
`1011
`
`
`1012
`
`
`1013
`
`
`1014
`
`1015
`
`
`1016
`
`1017
`
`
`1018-1019
`
`
`
`Fricke et al., “Lipid, Sterol and Fatty Acid Composition of
`Antarctic Krill (Euphausia superba Dana),” LIPIDS
`19(11):821-827 (1984) (Fricke I).
`
`Randolph, et al., U.S. Patent Application Publication No.
`US/2005/0058728 A1, “Cytokine Modulators and Related
`Method of Use” (Randolph).
`
`Sampalis [I] et al., “Evaluation of the Effects of Neptune Krill
`Oil™ on the Management of Premenstrual Syndrome and
`Dysmenorrhea” Altern. Med. Rev. 8(2):171-179 (2003)
`(Sampalis I).
`
`Sampalis [II] et al.,WO 2003/011873, published February 13,
`2003, “Natural Marine Source Phospholipids Comprising
`Flavonoids, Polyunsaturated Fatty Acids and Their
`Applications” (Sampalis II).
`
`Reserved.
`
`Tanaka et al., “Extraction of Phospholipids from Salmon Roe
`with Supercritical Carbon Dioxide and an Entrainer”, Journal of
`Oleo Science Vol. 53 (2004) No. 9, p.17-424 (Tanaka 2004).
`
`Reserved.
`
`Folch et al., “A simple method for the isolation and purification
`of total lipides from animal tissues”, J. Biol. Chem. (1957) 226:
`497-509 (Folch).
`
`Reserved.
`
`- i -
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`1020
`
`U.S. Patent No. 9,816,046
`
`
`1021-1023
`
`
`1024
`
`
`
`
`
`
`
`
`
`
`
`1025-1026
`
`1027
`
`
`1028
`
`
`1029
`
`1030
`
`
`1031
`
`
`
`Bunea, et al., “Evaluation Of The Effects Of Neptune Krill Oil
`On The Clinical Course Of Hyperlipidemia”, Altern Med Rev.
`2004; 9:420–428 (Bunea).
`
`Reserved.
`
`File History to U.S. Patent No. 9,034,388 B2, Serial No,
`12/057,775 (‘388 File History)
`1024 Part 1 - Pages 1-450
`1024 Part 2 - Pages 451-900
`1024 Part 3 - Pages 901-1350
`1024 Part 4 - Pages 1351-1800
`1024 Part 5A - Pages 1801-2025
`1024 Part 5B - Pages 2026-2250
`1024 Part 6 - Pages 2251-2700
`1024 Part 7 - Pages 2701-3083
`1024 Part 8 - Pages 3084-3223.
`
`
`
`
`
`Reserved.
`
`Saether et al., “Lipolysis post mortem in North Atlantic krill”.
`Comp. Biochem. Physiol. Vol. 83B, No. 1, pp. 51-55, 1986
`(Saether).
`
`Hawley’s Condensed Chemical Dictionary, p. 893, 13th
`ed.,1997 (Hawley’s)
`
`Reserved.
`
`Tehoharides, U.S. Patent Application Publication No.
`US/2006/0013905 A1, “Anti-Inflammatory Compositions For
`Treating Multiple Sclerosis” (Tehoharides).
`
`Reserved.
`
`- i -
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`1032
`
`
`U.S. Patent No. 9,816,046
`
`
`1033
`
`
`1034
`
`1035
`
`
`1036
`
`
`1037
`
`
`1038
`
`
`1039
`
`
`1040-1042
`
`
`
`Grantham, G.J., “The Utilization Of Krill”, UNDP/FAO
`Southern Ocean Fisheries Survey Programme (1977)
`(Grantham).
`
`Yoshitomi, U.S. Patent Application Publication No.
`US/2003/0113432 A1, “Process For Making Dried Powdery
`and Granular Krill” (Yoshitomi).
`
`Reserved.
`
`Breivik, U.S. Patent Application Publication No. US
`2010/0143571 A1, “Process for Production of Omega-3 Rich
`Marine Phospholipids from Krill” (Breivik I).
`
`Breivik, U.S. Provisional Patent Application No. 60/859,289,
`“Processes for production of omega-3 rich marine
`phospholipids from krill”, filed November 16, 2006 (Breivik
`‘289 Provisional, Breivik III).
`
`Breivik, WO 2008/060163 A1, “Process for Production of
`Omega-3 Rich Marine Phospholipids from Krill,” International
`filing date November 15, 2007 (Breivik II).
`
`Bottino, N.R., “Lipid Composition of Two Species of Antarctic
`Krill: Euphausia Superba and E. Crystallorophias”, Comp.
`Biochem. Physiol., 1975, Vol. 50B, pp. 479 to 484 (Bottino II).
`
`Grynbaum, M., et al. “Unambiguous detection of astaxanthin
`and astaxanthin fatty acid esters in krill (Euphausia superba
`Dana)”, J. Sep. Sci., 28, 1685–1693 (2005).
`
`Reserved.
`
`- ii -
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`1043
`
`U.S. Patent No. 9,816,046
`
`
`1044-1046
`
`1047
`
`1048-1053
`
`1054
`
`
`1055
`
`
`
`
`
`
`1056-1058
`
`1059
`
`
`1060-1062
`
`
`
`Bruheim, U.S. Patent Application Publication No.
`US2008/0274203 A1, published November 6, 2008 (this is the
`publication of patent application serial no. 12/057,775 which
`issued as U.S. Patent No. of 9,034,388).
`
`Reserved.
`
`U.S. Patent No. 9,034,388 B2, filed May 28, 2008 (‘388
`Patent).
`
`Reserved.
`
`Notice of Commission Determination ending Investigation 337-
`TA-1019, dated May 23, 2017.
`
`File History to U.S. Patent No. 9,375,453 B2, Serial No,
`14/020,162 (‘453 File History)
`
`1055 Part 1 - Pages 1-400
`1055 Part 2 - Pages 401-800
`1055 Part 3 - Pages 801-1109
`
`
`
`Markman Order (Public Version), Order 13, U.S. International
`Trade Commission, In the Matter of Certain Krill Oil Products
`and Krill Meal for Production of Krill Oil Products, Inv. No.
`337-TA-1019, dated April 13, 2017.
`
`Reserved.
`
`- i -
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`1063
`
`U.S. Patent No. 9,816,046
`
`File History to U.S. Patent No. 9,644,170 B2, Serial No,
`15/180,439 (‘170 File History)
`1063 Part 1 - Pages 1-400
`1063 Part 2 - Pages 401-800
`1063 Part 3 – Pages 801-1107.
`
`Reserved.
`
`U.S. Patent No. 9,375,453 B2, filed September 6, 2013 (‘453).
`
`U.S. Patent No. 9,028,877 B2, filed September 18, 2014 (‘877).
`
`Krill Bill Bottle and Capsules from IRL.
`
`Krill Bill Online Purchase Order and Specification Pages from
`2006 (https://web.archive.org/web/20060715103715/http://
`www.krillbill.com:80/purchase.htm;
`https://web.archive.org/web/20060715103809/http://www.krillb
`ill.com/profile.htm). See Exhibit 1076.
`
`Antarctica Select Krill Oil Online Literature and Purchase
`Order Form and linked FDA webpage from 2006
`(https://web.archive.org/web/20060816050841/http://www.aqu
`asourceproducts.com:80/store/;
`https://web.archive.org/web/20060816051010/http://www.aqua
`sourceproducts.com:80/krill_oil.html;
`https://web.archive.org/web/20060506115548/
`http://www.aquasourceproducts.com:80/resources.html?osCsid
`=aee4bb3df08470be3a75bc598448dabc;
`https://web.archive.org/web/20060513152744/http://vm.cfsan.f
`da.gov/~dms/ds-oview.html). See Exhibit 1076.
`
`
`
`
`1064-1066
`
`1067
`
`1068
`
`1069
`
`1070
`
`
`1071
`
`
`
`- i -
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`1072
`
`U.S. Patent No. 9,816,046
`
`
`1073-1074
`
`1075
`
`
`1076
`
`
`1077
`
`
`1078-1079
`
`1080
`
`
`
`Chen, U.S. Patent Application Publication No. US
`2008/0021000 A1, for “Mixtures of and Methods of Use for
`Polyunsaturated Fatty Acid-Containing Phospholipids and
`Alkyl Ether Phospholipids Species”, filing date July 19, 2006,
`publication date January 24, 2008.
`
`Reserved.
`
`Neptune, GRAS Notice [No. GRN 000242] for “High
`Phospholipid Krill Oil”
`https://www.fda.gov/downloads/Food/IngredientsPackagingLab
`eling/GRAS/NoticeInventory/ucm269133.pdf, dated January
`18, 2008 and filed by the FDA February 4, 2008 (Neptune
`GRAS); see also https://wayback.archive-
`it.org/7993/20170607013925/https://www.fda.gov/downloads/F
`ood/IngredientsPackagingLabeling/GRAS/NoticeInventory/UC
`M269133.pdf.
`
`Affidavit of Christopher Butler, Office Manager of Internet
`Archive, dated November 8, 2017, for Rimfrost Exhibits 1070
`and 1071, regarding Krill Bill, Aquasource and FDA related
`webpages from 2006.
`
`Pure Encapsulations online literature for its Krill-plex NKO™
`product, webpage from August 19, 2004.
`https://web.archive.org/web/20040819183137/www.purecaps.c
`om/itemdy00.asp?T1=KP1. See Exhibt 1092.
`
`Reserved.
`
`Hoem, N., “Composition of Antarctic krill oil and methods for
`its harvesting, production and qualitative and quantitative
`analysis”, Aker BioMarine, Newcastle Australia November
`2013 (Hoem).
`
`- i -
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`
`1081-1083
`
`1084
`
`Reserved.
`
`U.S. Patent No. 9,816,046
`
`Mayzaud et al, “Changes in lipid composition of the Antarctic
`krill Euphausia superba in the Indian sector of the Antarctic
`Ocean: influence of geographical location, sexual maturity
`stage and distribution among organs” Marine Ecology Progress
`Series, Vol. 173: 149-162 (1998) (Mayzaud).
`
`Reserved.
`
`Affidavit of Christopher Butler, Office Manager of Internet
`Archive, dated February 5, 2018, regarding Rimfrost
`Exhibit 1077, Pure Encapsulations online literature for its Krill-
`plex NKO™ product, webpage from August 19, 2004.
`
`U.S. Patent No. 9,644,170 B2, filed June 13, 2016 (‘170)
`
`Reserved.
`
`Britton, G., Structure and properties of carotenoids in relation
`to function, FASEB J, 9, 1551-1558,1995.
`
`Yuan, “Characteristics and chromatographic separation of
`astaxanthin and its esters from the microalga Haematococcus
`pluvialos,” Doctoral Thesis, The University of Hong Kong,
`1999 (http://dx.doi.org/10.5353/th_b3123971).
`
`Mimoun-Benarroch, et al., The Bioavailability of Astaxanthin is
`Dependent on both the Source and the Isomeric Variants of the
`molecule, Bulletin of University of Agricultural Sciences and
`Veterinary Medicine Cluj-Napoca: Food Science and
`Technology, Volume 73, Number 2, 2016, pp. 61-69(9).
`
`- ii -
`
`1085-1091
`
`1092
`
`
`
`
`1093
`
`1094-1096
`
`1097
`
`
`1098
`
`
`1099
`
`
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`1100
`
`U.S. Patent No. 9,816,046
`
`
`1101
`
`
`1102
`
`
`1103
`
`
`1104
`
`
`1105-1109
`
`1110
`
`1111
`
`
`1112
`
`1113
`
`
`1114
`
`
`
`Higuera-Ciapara, et al., Astaxanthin: A Review of its Chemistry
`and Applications, Crit Rev Food Sci Nutr. 2006;46(2):185-96.
`
`Lambertsen, et al., Method of Analysis of Astaxanthin and its
`Occurrence in some Marine Products, J. Sci. of Food and
`Agriculture, 1971, Vol. 22, February.
`
`Foss, et al., Natural occurrence of enantiomeric and Meso
`
`astaxanthin 7∗-crustaceans including zooplankton,
`
`Comparative Biochemistry and Physiology Part B:
`Comparative Biochemistry, Volume 86, Issue 2, 1987, Pages
`313-314.
`
`Final Written Decision, IPR2017-00745, August 10, 2018,
`Paper 24 (U.S. Patent No. 9,078,905).
`
`Final Written Decision, IPR2017-00746, August 10, 2018,
`Paper 23 (U.S. Patent No. 9,028,877).
`
`Reserved.
`
`U.S. Patent No. 9,644,169, issued May 9, 2017.
`
`File History for U.S. Patent No. 9,644,169, serial no.
`15/180,431.
`
`Reserved.
`
`File History for U.S. Patent No. 9,816,046, serial no.
`15/589,572.
`
`U.S. Patent No. 10,010,567, issued July 3, 2018.
`
`- i -
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`1115
`
`U.S. Patent No. 9,816,046
`
`
`1116
`
`1117
`
`1118
`
`1119-1128
`
`1129
`
`
`1130-1153
`
`1154
`
`
`1155
`
`
`1156
`
`
`1157
`
`
`1158
`
`
`
`File History for U.S. Patent No. 10,010,567, serial no.
`15,589,605.
`
`U.S. Patent No. 9,078,905 B2, issued July 14, 2015.
`
`U.S. Patent No. 9,320,765 B2, issued April 26, 2016.
`
`U.S. Patent No. 9,072,752 B2, issued July 7, 2015.
`
`Reserved.
`
`Final Written Decision, IPR2018-00295, June 12, 2019, Paper
`35 (U.S. Patent No. 9,320,765).
`
`Reserved.
`
`Aker Biomarine Antarctic AS v. Rimfrost AS, Nos. 2019-1097,
`2019-1078 (Fed. Cir. Oct. 3, 2019)
`
`Inter Partes Review Certificate US 9,028,877 Kl cancelling all
`claims of U.S. Patent No. 9,028,877, issued March 12, 2020.
`
`Inter Partes Review Certificate US 9,078,905 Kl cancelling all
`claims of U.S. Patent No. 9,078,905, issued March 11, 2020.
`
`Final Written Decision Determining All Challenged Claims
`[claims 1–32] Unpatentable and Denying Patent Owner’s
`Motion to Amend, IPR2018-01178, Patent 9,375,453 B2, dated
`January 13, 2020.
`
`Final Written Decision Determining All Challenged Claims
`[claims 33–61] Unpatentable and Denying Patent Owner’s
`Motion to Amend, IPR2018-01179, Patent 9,375,453 B2, dated
`January 13, 2020.
`
`- i -
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`1159
`
`U.S. Patent No. 9,816,046
`
`
`1160-1166
`
`1167
`
`
`
`
`Final Written Decision Determining All Challenged Claims
`[claims 1-20. i.e., all claims] Unpatentable and Denying Patent
`Owner’s Motion to Amend, IPR2018-01730, Patent 9,072,752
`B2, dated March 6, 2020.
`
`Reserved.
`
`Ballantine, J.A., Roberts, J.C., and Morris, R.J. (1980), “Marine
`Sterols. XII. The Sterols of Some Pelagic Marine Crustaceans”
`J. Exp. Mar. Biol. Ecol. 47, 25-33.
`
`
`
`- ii -
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`I.
`
`INTRODUCTION
`Petitioner, real party-in-interest, Rimfrost AS, a Norwegian corporation
`
`U.S. Patent No. 9,816,046
`
`with its principal place of business at Vågsplassen, 6090, Fosnavåg, Norway,
`
`petitions the Patent Trial and Appeal Board ( “Board” or “PTAB”) of the United
`
`States Patent and Trademark Office (“PTO”), pursuant to 35 U.S.C. §§ 311-319
`
`and 37 C.F.R. § 42.1 et seq., to institute an inter partes review and to find
`
`unpatentable and cancel claims 1-19 of U.S. Patent No. 9,816,046, entitled
`
`“Bioeffective Krill Oil Compositions” (“the ‘046 patent”) (Exhibit 1001) which is
`
`assigned to Aker Biomarine Antarctic AS (“Aker”).
`
`The Board should now be well versed in the subject matter recited and
`
`claimed in the challenged ‘046 patent. On six prior occasions, the Board issued
`
`Final Written Decisions finding all claims of five Aker patents sharing the same
`
`specification and reciting identical subject matter unpatentable:
`
`•
`
`•
`
`•
`
`U.S. Patent No. 9,028,877 (“the ‘877 patent”)
`IPR2017-00746, Paper 23 (PTAB Aug. 10, 2018) (“877 FWD”);
`
`U.S. Patent No. 9,078,905 (“the ‘905 patent”)
`IPR2017-00745, Paper 24 (PTAB Aug. 10, 2018) (“905 FWD”);
`
`U.S. Patent No. 9,320,765 (“the ‘765 patent”)
`IPR2017-00295, Paper 35 (PTAB June 12, 2019) (“765 FWD”);
`
`
`
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`
`•
`
`U.S. Patent No. 9,816,046
`
`U.S. Patent No. 9,375,453 (“the ‘453 patent”)
`IPR2018-01178, Paper 34 (PTAB Jan. 13, 2020) (“453 FWD I”)
`IPR2018-00179, Paper 34 (PTAB Jan. 13, 2020) (“453 FWD II”);
`and
`
`U.S. Patent No. 9,072,752 (“the ‘752 patent”)
`IPR2018-01730, Paper 35 (PTAB March 6, 2020) (“752 FWD”).
`
`In each of these Final Written Decisions, the Board evaluated claim
`
`•
`
`limitations that are materially similar, if not identical, to those recited in the
`
`claims of the ‘046 patent. Notably, the Federal Circuit affirmed
`
`877 FWD and 905 FWD. Additionally, Patent Owner failed to seek appellate
`
`review of 453 FWD I, 453 FWD II and 752 FWD.
`
`The Board should also be familiar with the prior art relied on by Petitioner
`
`in challenging the claims of the ‘046 patent. With the exception of a single prior
`
`art reference disclosing krill meal storage, each reference in this Petition was
`
`applied and relied on in one or more of the Board’s previous Final Written
`
`Decisions. Given the materially identical claim limitations and common prior art,
`
`collateral estoppel should control the majority of issues needed to evaluate the
`
`patentability of the claims of the ‘046 patent.
`
`
`
`
`
`
`
`2
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`
`U.S. Patent No. 9,816,046
`
`At bottom, there is a reasonable likelihood that Petitioner will prevail with
`
`respect to at least one claim challenged in this Petition. Petitioner respectfully
`
`requests that the Board institute trial on all claims of the ‘046 patent.
`
`II. MANDATORY NOTICES
`A. Real parties-in-interest
`
`Olympic Holding AS, Emerald Fisheries AS, Rimfrost USA, LLC,
`
`Rimfrost New Zealand Limited, Bioriginal Food and Science Corp., and
`
`Petitioner, Rimfrost AS, are identified as the real parties-in-interest. Several other
`
`entities have a majority ownership interest in the above-identified real parties-in-
`
`interest. Based on those ownership interests, and in an abundance of caution,
`
`Petitioner also names Stig Remøy, SRR Invest AS, Rimfrost Holding AS and
`
`Omega Protein Corporation as real parties-in-interest.
`
`B. Related matters (37 C.F.R. § 42.8(b)(2))
`
`Aker previously asserted the ‘877 and ‘905 patent in a lawsuit captioned Aker
`
`Biomarine Antarctic AS v. Olympic Holding AS; Rimfrost AS; Emerald Fisheries AS,
`
`Rimfrost USA, LLC; Avoca Inc.; and Bioriginal Food & Science Corp. Case No.
`
`1:16-CV-00035-LPS-CJB (D. Del.). This litigation was initially stayed in view of
`
`Investigation No. 337-TA-1019 instituted by the United States International Trade
`
`
`
`3
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`Commission on September 16, 2016 as noticed in the Federal Register. The ITC
`
`U.S. Patent No. 9,816,046
`
`proceeding was entitled In the Matter of Certain Krill Oil Products and Krill Meal
`
`for Production of Krill Oil Products and involved to the ‘877 and ‘905 patents, as
`
`well as Patent Owner’s related ‘765, ‘453 and ‘752 patents. The ITC investigation
`
`identified Olympic Holding AS, Rimfrost AS, Emerald Fisheries AS, Avoca Inc.,
`
`Rimfrost USA, LLC, Rimfrost New Zealand Limited and Bioriginal Food & Science
`
`Corp. as respondents.
`
`On May 23, 2017, ITC Investigation No. 337-TA-1019 was terminated.
`
`Exhibit 1054. In addition, a Stipulation of Dismissal as to Avoca, Inc. was granted
`
`by the Delaware District Court on May 30, 2017.
`
`On January 27, 2017, Petitioner filed petitions in IPR2017-00745 and
`
`IPR2017-0747 requesting review of claims 1-20 of the ‘905 patent. On February 3,
`
`2017, Petitioner filed petitions in IPR2017-0746 and IPR2017-00748 requesting
`
`review of claims 1-19 of the ‘877 patent. Each was instituted on August 16, 2017.
`
`On September 6, 2017, the Delaware District Court action was stayed pending
`
`resolution of these IPRs. On August 24, 2018, the Board ruled that claims 1-20 of
`
`
`
`
`
`
`
`4
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`the ‘905 patent and claims 1-19 of the ‘877 patent are unpatentable. 905 FWD
`
`U.S. Patent No. 9,816,046
`
`(Exhibit 1103); 877 FWD (Exhibit 1104).
`
`On October 3, 2019, the U.S. Court of Appeals for the Federal Circuit, in a
`
`consolidated opinion, affirmed the Board’s Final Written Decisions in IPR2017-
`
`00745 and IPR2017-00746 finding all claims of the ‘877 and ‘905 patents
`
`unpatentable. Aker Biomarine Antarctic AS v. Rimfrost AS, 786 F. App’x 251
`
`(2019) (Exhibit 1154). On October 28, 2019, based on the Federal Circuit’s
`
`affirmance of 877 FWD and 905 FWD, the Delaware District Court action was
`
`dismissed with prejudice.
`
`In March 2020, the Patent Office issued Inter Partes Review Certificates
`
`cancelling claims 1-19 of the ‘877 patent and claims 1-20 of the ‘905 patent.
`
`Exhibits 1155, 1156.
`
`On December 15, 2017, Petitioner filed a petition in IPR2018-00295
`
`requesting review of claims 1-48 of the ‘765 patent. This IPR was instituted on June
`
`14, 2018. On June 12, 2009, the Board issued a Final Written Decision finding all
`
`claims of the ‘765 patent unpatentable. 765 FWD (Exhibit 1129). As part of its
`
`Final Written Decision, the PTAB also denied Patent Owner’s contingent Motion to
`
`
`
`5
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`Amend that sought to replace claims 25-32 with substitute claims 49-56. On July
`
`U.S. Patent No. 9,816,046
`
`12, 2019, Patent Owner filed a Request for Rehearing limited exclusively to the
`
`Board’s denial of the Motion to Amend. On November 22, 2019, the Board granted
`
`the Request for Rehearing, which is now fully briefed, and the Board’s ruling on the
`
`patentability of the substitute claims remains pending.
`
`On February 9, 2018, Petitioner filed a petition in PGR2018-0033 requesting
`
`review of claims 1-20 of U.S. Patent No. 9,644,170 (“the ‘170 patent”). On August
`
`29, 2018, the Board determined that the ‘170 patent was not eligible for post grant
`
`review.
`
`On June 26, 2018, Petitioner filed petitions in IPR2018-01178 and
`
`IPR2018-01179 requesting review of claims 1-31 and claims 32-61 of the ‘453
`
`patent, respectively. Both proceedings were instituted on January 14, 2019. On
`
`January 13, 2020, the Board issued Final Written Decisions finding claims 1-31 and
`
`claims 32-61 unpatentable. 453 FWD I (Exhibit 1157); 453 FWD II (Exhibit 1158).
`
`The Board also denied Patent Owner’s contingent motions to amend. Patent Owner
`
`did not appeal either of these Final Written Decisions.
`
`
`
`
`
`
`
`6
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`
`U.S. Patent No. 9,816,046
`
`On September 21, 2018, Petitioner filed a petition in IPR2018-01730
`
`requesting review of claims 1-20 of the ‘752 patent. This IPR was instituted on May
`
`12, 2019. On March 6, 2020, the Board issued a Final Written Decision finding
`
`claims 1-20 unpatentable, and denied Patent Owner’s contingent motion to amend.
`
`752 FWD (Exhibit 1159). Patent Owner did not appeal the Board’s decision.
`
`On September 30, 2020, Petitioner filed a petition in IPR2020-01532
`
`requesting review of claims 1-20 of U.S. Patent No. 9,644,169 (“the ‘169 patent”).
`
`The ‘169 patent, like the ‘046 patent, is in the same patent family and shares a
`
`common specification with the ‘877, ‘905, ‘765, ‘453 and ‘752 patents which have
`
`already been adjudicated unpatentable.
`
`C. Counsel (37 C.F.R. §§ 42.8(b)(3) and 42.10(a))
`Petitioner designates the following individuals as its lead counsel and back-
`
`up lead counsel:
`
`Lead Counsel:
`
`Back-Up Counsel:
`
`James F. Harrington
`Reg. No. 44,741
`Hoffmann & Baron, LLP
`jfhdocket@hbiplaw.com
`(516) 822-3550
`
`
`
`
`
`Michael I. Chakansky
`Reg. No. 31,600
`Hoffmann & Baron, LLP
`micdocket@hbiplaw.com
`(973) 331-1700
`
`
`
`7
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`
`
`
`D.
`
`U.S. Patent No. 9,816,046
`
`John T. Gallagher
`Reg. No. 35,516
`Hoffmann & Baron, LLP
`jtgdocket@hbiplaw.com
`(516) 822-3550
`
`Service information (37 C.F.R. § 42.8(b)(4))
`
`Service on Petitioner may be made electronically by using the following
`
`email address: 046ipr@hbiplaw.com and the email addresses above. Service on
`
`Petitioner may be made by Postal Mailing or Hand-delivery addressed to Lead and
`
`Back-up Counsel at the following address, but electronic service above is
`
`requested:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Hoffmann & Baron, LLP
`6900 Jericho Turnpike
`Syosset, New York 11791
`
`This Petition with all associated exhibits has been served on the patent
`
`owner at its corporate headquarters, Oskenøyveien 10 No-1327, 1366 Lysaker,
`
`Norway, as well as the correspondence address of record for the ‘169 patent:
`
`Casimir Jones, S.C., 2275 Deming Way, Suite 310, Middleton, Wisconsin 53562.
`
`
`
`
`
`
`
`8
`
`

`

`Inter Partes Review Case No.: IPR2020-01533
`
`
`III. PATENT OFFICE FEES
`Pursuant to 37 C.F.R. §§ 42.103 and 42.15(a), the requisite filing fee of
`
`U.S. Patent No. 9,816,046
`
`$32,900 (request fee of $15,500, post-institution fee of $15,000 and excess claims
`
`fee of $2,400) for a Petition for Inter Partes Review is submitted herewith.
`
`Claims 1-19 of the ‘046 patent are being reviewed as part of this Petition. The
`
`undersigned further authorizes payment from Deposit Account No. 08-2461 for
`
`any additional fees or refund that may be due in connection with the Petition.
`
`IV. ADDITIONAL REQUIREMENTS FOR INTER PARTES REVIEW
`A. Grounds for Standing (37 C.F.R. § 42.104(a))
`Petitioner certifies the ‘046 patent is available for Inter Partes Review, and
`
`Petitioner is not barred or estopped from requesting Inter Partes Review
`
`challenging the claims of the ‘046 patent on the grounds detailed below.
`
`Level or Ordinary Skill in the Art
`B.
`As of the earliest priority date the

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket